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Objectives: Upon completion of this article, the reader will
be able to describe the history and current state of prostatic
artery embolization (PAE) for the treatment of lower uri-
nary symptoms secondary to benign prostatic hyperplasia.
This will include the advantages of PAE compared with
traditional surgical therapy, overall clinical outcomes, and
future directions of research needed to further validate this
technique.
Accreditation: This activity has been planned and imple-
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the Accreditation Council for Continuing Medical Education
(ACCME) through the joint providership of Tufts University
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New York. TUSM is accredited by the ACCME to provide
continuing medical education for physicians.
Credit: Tufts University School of Medicine designates this
journal-based CME activity for a maximum of 1 AMA PRA
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Lower urinary tract symptoms (LUTSs) are a common
malady in elderly men1 that include storage, voiding, and
postmicturition symptoms, and are related to both bladder
outlet obstruction and irritation caused by benign prostatic
hyperplasia (BPH).2 While mild LUTS can be treated with
lifestyle modifications, patients with moderate-to-severe
LUTS may benefit from medical therapy, including α-adren-
ergic blockers, 5-α-reductase inhibitors, muscarinic receptor
antagonists, and phosphodiesterase inhibitors.3
Prostate surgery is indicated in patients with medical refrac-
tory LUTS secondary to BPH. Transurethral resection of the
prostate (TURP) is regarded as the surgical gold standard for
men with mild-to-moderate prostatic enlargement. There is an
average hospital stay of 2.6 days after TURP and potential
complications include TUR syndrome (electrolyte imbalance
secondary to saline infusion), acute urinary retention, urinary
tract infection, bladder neck stenosis, urethral stricture, retro-
grade ejaculation, erectile dysfunction, urinary incontinence,
and bleeding requiring transfusion.4 Open prostatectomy (OP)
is the first-line surgical option for menwith very large prostates
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Abstract Prostatic artery embolization (PAE) is an emerging, novel interventional technique in the
management of patients with lower urinary tract symptoms (LUTS) secondary to benign
prostatic hyperplasia (BPH). BPH is a common clinical condition in middle-aged and
elderly men resulting in LUTS, including nocturia, urinary frequency, urgency, decreased
urinary flow rates, hesitancy, and incomplete bladder emptying. Traditionally, LUTSs
have been managed by medical or surgical therapies. Since the initial incidental
discovery that selective PAE performed for uncontrolled bleeding secondary to BPH
resulted in improved LUTS, the technique has continually evolved with a growing body of
evidence supporting its safety and efficacy. However, despite the available data, PAE has
yet to be established as a standard-of-care treatment option for patients with LUTS/BPH.
In this article, the authors review the history and current state of PAE, including
published data from case reports, animal studies, retrospective/prospective cohort
studies, and prospective randomized controlled trials.
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and associated hospital stays average 9.2 days.5 Complications
associated with OP includemortality, blood transfusion, urinary
incontinence, and bladder neck stenosis or urethral stricture.3
Owing to perioperative complications associated with
TURP and OP, less invasive alternative options have been
developed. In lieu of TURP photoselective vaporization of the
prostate (PVP), transurethral needle ablation (TUNA), trans-
urethral incision of the prostate (TUIP), transurethral micro-
wave therapy (TUMT), and prostatic urethral lift (PUL) all have
Food and Drug Administration–approved indications for
treatment of BPH. For more severe prostate enlargement,
laparoscopic or robot-assisted prostatectomyor transurethral
holmium laser enucleation of the prostate (HoLEP) provide
less invasive alternatives to OP.
Recently, prostatic artery embolization (PAE) has been
proposed as a safe and effective alternative to alleviate
LUTS secondary to BPH.6 In contrast to surgical treatments,
PAE has the advantages of being a minimally invasive, outpa-
tient procedure with a short recovery time and a low risk of
major complications. However, although available data show
promising results, further study will be required for PAE to
become part of the standard-of-care treatment algorithm for
patients with LUTS secondary to BPH. The aim of this article is
to review the history, the technique, the outcomes, and the
current state of PAE, summarizing the published data from
early case reports, animal studies, retrospective/prospective
cohort studies, and recent prospective randomized con-
trolled trials (RCTs).
History: Transcatheter Arterial Embolization
for Refractory Hematuria
Since Mitchell et al7 first reported four cases of transcatheter
arterial embolization of bilateral internal iliac arteries for man-
aging severe hematuria, the technique has been widely used as
an effective and safe treatment modality for patients with life-
threatening intractable bleeding either from the bladder or
prostate when all other measures have failed.7–14 With the
development of microcatheters, the technique has evolved
from nonselective embolization of the internal iliac artery to
more selective catheterization of its branch arteries.14–16
In 2000, DeMeritt et al16 first discovered the benefit of PAE
for treating LUTS. A 76-year-old man with intractable hema-
turia secondary to BPHwas treated with transcatheter arterial
embolization. The authors subselectively embolized the right
inferior vesical artery using 150 to 250 µm polyvinyl alcohol
until complete devascularization of the prostate. Left-sided
branches were not treated due to severe atherosclerosis of the
internal iliac artery. At 12-month follow-up, the patient’s
International Prostate Symptom Score (IPSS), a questionnaire
scoring the severity of LUTS, was improved from 24 to 13 with
a reduction of prostate volume (PV) from 305 to 190mL (40%).
Animal Study
The first animal study was conducted in 1980 by Darewicz on
five dogs, investigating the changes in the prostate gland after
embolization of the internal iliac arteries.17 The purpose of
this experiment was to evaluate the potential role of internal
iliac artery embolization as a treatment option for hemor-
rhage from the prostate gland. Four weeks after transcatheter
embolization of the internal iliac arteries using N-butyl-2-
cyanoacrylate acid, prostates did not reveal any changes on
macroscopic examination. However, under the microscope,
infiltrations of lymphocytes, histiocytes, and fibroblasts were
observed in the interstitial tissue of the prostate. The authors
concluded that embolization of the internal iliac arteries may
be useful in the treatment of prostatic hemorrhage in clinical
practice, because the technique does not result in anymarked
gross changes in the prostatic gland.
Later, Sun et al18 evaluated the technical feasibility and safety
of PAE inpigs in 2008. Sixteenpigswere randomlyassigned to an
embolization or control group. PAE was successful in all eight
pigs usingmicrospheres (500–700 µm). Threemonths after PAE,
the mean PV was significantly reduced in the embolization
group (p < 0.001) without significant difference in sexual func-
tion between the two groups (p ¼ 0.328). Histologic examina-
tion revealed decreased glandular tissue with interdigitating
fibrosis. Based on the results, the authors suggested that PAE has
potential for treating symptomatic BPH in humans without a
compromise in sexual function.
The same group evaluated pathologic responses of the
prostate to PAE in seven canine models with hormonally
induced BPH in 2011. PAEwas performed using 500 to 700 µm
microspheres without complications. One month after PAE,
prostatic infarction was identified on imaging studies and
necropsy.19 This further supported the notion that evaluation
of the procedure in humans was warranted.
Anatomy of Prostatic Arteries
Because of the small size of the prostatic arteries (PAs), its
anatomic complexity, and variations, it is often challenging to
identify theorigins of thePAs, differentiate thePAs fromadjacent
arterial branches, and detect small arterial anastomoses. To
perform successful PAE without nontarget embolization, it is
essential to have comprehensive knowledge of the vascular
anatomy and its relationship with surrounding structures.
In 1955, PA anatomy was studied by Clegg in a cadaveric
study with 21 pelvic halves.20 He described that the prostate
glandwas supplied by the prostatovesical arterywhichwas of
variable origin. Clegg also noted that terminal branches of the
PA continued to the rectum and anal canal to form themiddle
rectal arteries. He also described a characteristic “corkscrew”
pattern of fine branches of PA on the surface of the prostate as
they penetrated into the stroma of the gland.
The presence of two independent PAs (cranial and caudal
PAs) on each pelvic side was first discovered in 1959 by
Bouissou and Talazac.21 In their cadaveric study with 100
pelvic halves, they compared the PA anatomy in the setting of
a normal prostate versus BPH or prostate cancer. They
described that the cranial PA (vesicoprostatic artery) ran
between the bladder and prostate, supplying the bladder
base, and central and cranial prostate. The cranial PA was
often enlarged in the setting of BPH. On the other hand, the
caudal PA was found to course posteriorly, passing between
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the rectum and the posterior surface of the prostate, supply-
ing the peripheral and caudal prostate.
Bilhim et al22 in 2012 studied PA anatomy using computed
tomography angiography (CTA) and digital subtraction angi-
ography (DSA) in 75 patients with BPH who underwent PAE.
In their study of 150 pelvic halves, a solitary PA and two
independent PAs were found in 57 and 43% of pelvic halves,
respectively. The PAs had variable origins, including the
internal pudendal artery (34%), a common trunk with supe-
rior vesical artery (20.2%), the gluteal-pudendal trunk
(17.8%), the obturator artery (12.6%), and a common trunk
with rectal branches (8.4%). In 57% of pelvic halves, PAs were
anastomosed with adjacent pelvic arteries, such as the inter-
nal pudendal arteries (43.3%), contralateral PAs (17.6%),
ipsilateral PAs (13.4%), rectal arteries (14.4%), vesical arteries
(11.3%), and lateral accessory pudendal arteries (20%). They
found no significant correlation between PA diameter and
patient age, PV, or prostate-specific antigen (PSA) level.
Cone-beam CT (CBCT) can also be used for pelvic vascular
mappingwith its three-dimensional imaging capability. In 2015,
Zhang et al evaluated PA anatomy using intraprocedural CBCT
and DSA in 55 patients (110 pelvic halves) with BPH who
underwent PAE.23 The results were somewhat different from
the previous study by Bilhim et al. The incidences of a solitary PA
and two independent PAs in this study were 96.4 and 3.6%,
respectively. The PAs againwere found to originate from various
pelvic arteries, including the anterior division of the internal iliac
artery (39.5%), the superior vesical artery (32.6%), and the
internal pudendal artery (27.9%). The authors also found that
the PA often anastomosed with adjacent pelvic arteries outside
the prostate (39.1%) as well as with the contralateral PA within
the prostate gland (39.1%). In conclusion, they suggested that
CBCT can be helpful for identifying the PA anatomy when
preprocedural pelvic CTA is not available.
Techniques and Outcomes of PAE
Successful PAE in humans with acute urinary retention sec-
ondary to BPH was first reported by Carnevale et al in 2010.24
In two patients, PAE was performed using 300 to 500 µm
microspheres and both demonstrated relief of urinary obstruc-
tion and reduction of PV at 6-month follow-up. Intravesical
prostate protrusion and postvoid residual urine volume (PVR)
were also diminished in both patients. Later in 2011, the same
group published the midterm follow-up results for the same
two patients demonstrating durability of the PV loss and
symptomatic improvement to 30 months.25
In 2011, a case series evaluating feasibility of PAE in
patients with LUTS was published by Pisco et al.26 PAE was
technically successful in 14 of the 15 patients. There was
significant IPSS reduction, improved quality of life (QoL),
increase in urinary peak flow rate (Qmax), and PV reduction.
There was one major complication (bladder ischemia that
required surgical resection) and four clinical failures (28.6%).
This small case series was then later expanded to include
89 patients by the same group in 2013.27 At 1-month follow-
up, mean IPSS decreased by 10 points, mean QoL score
decreased by 2 points, mean Qmax increased by 38%, mean
PV decreased by 20%, mean PVR decreased by 30 mL, and the
mean international index erectile function (IIEF) score
increased by 0.5 point (all differences at p < 0.01). Besides
the bladder ischemia described in their previous paper, no
additional major complications were reported.
The same group published again in 2013 on an expanded
sample size now numbering 255 patients. Midterm results
with amean follow-up of 10months were reported.28Overall
technical success rate of PAE (unilateral embolization) was
97.9%. Cumulative rates of clinical success were 81.9, 80.7,
77.9, 75.2, 72.0, 72.0, 72.0, and 72.0% at 1, 3, 6, 12, 18, 24, 30,
and 36 months, respectively.
In 2013, Antunes et al described the efficacy of PAE in 11
patients with urinary retention due to BPH.29 Clinical success
was 91%with amean follow-up of 22.3months. At thefirst year
follow-up, themean IPSS scorewas 2.8 points,meanQoLwas 0.4
points, mean PSA decreased from 10.1 to 4.3 ng/mL, Qmax
improved from 4.2 to 10.8 mL/s, and detrusor pressure
decreased from85.7 to 51.5 cmH2O. In this study, overall clinical
and urodynamic parameters were significantly improved after
PAE. Carnevale et al also reported updated results of PAE in
2013.30 Their technical and clinical success rates were 75 and
91%, respectively,with nomajor complications. At 1-year follow-
up, mean PV reduction was greater than 30%, symptoms were
mild (mean IPSS, 2.8  2.1), no erectile dysfunction was
observed, and QoL improved significantly (mean, 0.4  0.5).
Bagla et al31 reported early results from aU.S. trial of PAE in
2014. Bilateral PAEwas successful in 18 of 19 patients in their
cohort without any complications. One case of unilateral PAE
was due to atherosclerotic change of the contralateral PA.
Clinical successwas found in 19 of 20 patientswith significant
improvement of the American Urological Association (AUA)
symptom score (equivalent to IPSS) and QoL. PV was
decreased by 18% at 6 months.
In 2014, Kurbatov et al studied clinical benefits and safety
of PAE in patients with PV greater than 80 mL.32 In this
nonrandomized prospective study, PAE was performed in 88
patients affected by clinical benign prostatic obstruction. The
mean IPSS (10.40 from 23.98) and the mean Qmax (16.89
from 7.28) at 1 year were significantly improved compared
with baseline. PVR, total PV, and PSA level were also signifi-
cantly improved at 1-year follow-up.
In 2014, the first RCT of PAE versus TURP was reported by
Gao et al from China.33 A total of 114 patients with BPH were
randomly assigned to PAE (n ¼ 57) or TURP (n ¼ 57). All the
clinical metrics (IPSS, QoL, Qmax, PVR, PSA, and PV) were
significantly improved in both groups comparedwith baseline.
However, in the TURP group, improvements of IPSS, QoL,
Qmax, and PVR were greater at 1 and 3 months compared
with PAE group. Reduction in PSA level and PV were also
greater in TURP group at all follow-up time points compared
with PAE group. At 2-year follow-up, however, there was no
significant difference of any of the clinical metrics between the
two groups. Rates of overall adverse events and complications
were higher in the PAE group compared with TURP group. It
should benoted, however, that postembolization and technical
and clinical failures were included as complications. PAE was
associated with shorter hospital stay compared with TURP.
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In the United Kingdom, preliminary results of PAE in 35
patients with very symptomatic BPH (mean IPSS, 24; mean
PV, 94.9 mL) were reported by Somani et al in 2014.34 A
technical success ratewas 100% (bilateral PAE, 90%; unilateral
PAE, 10%). The mean IPSS and health-related QoL score at
6 months were 12 and 2, respectively. PV was reduced by 42%
with an increase of Qmax by 32%. There were no major
complications related to PAE.
In 2015, Bagla et al also expanded their previous U.S. trial of
PAE to 78 patients.35 They evaluated AUA symptom index, QoL,
and IIEF between three groupswith different PV (group 1with
PV < 50 mL, group 2 with PV of 50–80 mL, group 3 with
PV < 80 mL). Bilateral PAE was successful in 75 of 78 patients
with only twominor complications, including groinhematoma
and urinary tract infection. The authors demonstrated a
significant reduction in AUA symptom index and QoL in all
three groups. Therewere no statistically significant differences
in AUA symptom index, QoL, or IIEF between the groups.
In 2015, de Assis et al published a single-center, single-arm
prospective study of PAE for treating LUTS secondary to BPH
in 35 patients with PV greater than 90 mL.36 At 3-month
follow-up, PV, IPSS, and QoL were significantly improved
compared with baseline values before PAE (p < 0.001).
They observed a significant negative correlation between
PSA at 24 hours after PAE and IPSS at 3-month follow-up.
Amouyal et al reported their first experience of PAE using
proximal embolization first then embolize distal (PEr-
FecTED) technique for treating LUTS in 35 consecutive pa-
tients with BPH in 2015.37 Although The PErFecTED
technique was originally introduced by Carnevale et al38 in
2014, there had been no data reported outside from the Sao
Paulo group that initiated this technique. Overall immediate
technical success of PAE was 100% and PErFecTED technique
was feasible in 68% of patients. There were significant
improvements in IPSS, QoL, Qmax, and PV compared with
baseline values. There were no major complications. The
authors concluded that the PErFecTED technique is
feasible, safe, and effective in the management of LUTS
related to BPH. In some cases, this technique was not feasible
for anatomic reasons.
Later in 2015, Wang et al published midterm follow-up data
of PAE in the treatmentof BPHwith PVgreater than80mL in105
Chinese patients with BPH.39 PAEwas performed using particles
with combination of 50 and 100 μm in diameter. At 24-month
follow-up, IPSS, QoL, Qmax, PVR, and PV were significantly
improved compared with baseline. They concluded that a large
prostate does not add an increased risk of complications.
In 2016, aRCTof PAEversus TURPwaspublishedbyCarnevale
et al.40 They compared clinical and urodynamic outcomes of
TURP to original PAE and PAE with PErFecTED technique in
patients with BPH. Initially, a total of 30 patients were randomly
assigned to either TURP (n ¼ 15) or original PAE (n ¼ 15), but
later an additional 15patientswhowerematchedwith theTURP
patients using urodynamic metrics were enrolled in a separate
arm to evaluate PErFecTED PAE technique. In all groups, IPSS,
QoL, PV, and Qmax were significantly improved. IPSS was
significantly lower in both the TURP group and the PErFecTED
PAE group compared with original PAE group. However, there
was no significant difference between TURP and PErFecTED PAE
groups. Complications resulted from TURP included urinary
incontinence (26.7%), rupture of the prostatic capsule (6.7%),
retrograde ejaculation (100%), and readmission for temporary
bladder irrigation due to hematuria. The authors concluded that
TURP and PErFecTED PAE provide similar clinical outcomeswith
better urodynamic results.
Future Direction in Prostatic Artery
Embolization Study
Although there are multiple single-arm studies demonstrat-
ing PAE is safe and effective in reducing LUTS, the amount of
RCT data are limited. In addition, longer longitudinal data are
needed to understand the durability of the urinary improve-
ment that results from PAE. Future study designs should
include multicenter, prospective RCTs for comparing PAE
and other BPH therapies including OP, TURP, and other
transurethral therapies with multiple-year follow-up.
Additional questions that need to be answered include
determining the optimal type and size of embolic material,
the benefit of a robotic catheter for challenging anatomy, the
optimal technique for preventing embolic flow to nontarget
organs through PA anastomoses, the potential benefit of a
transradial approach, and the optimal pre- and intraproce-
dural imaging techniques.
Conclusion
Based on the available data, PAE appears to be an effective and
safe minimally invasive technique to treat LUTS resulting
from BPH. PAE has the advantage of being an outpatient
procedure that requires only local anesthesia or moderate
sedation. Because PAE can be technically challenging even for
experienced interventional radiologists, the mastery of the
anatomy and high-quality pre- and intraprocedural imaging
is important. To solidify PAE’s place in the BPH treatment
algorithm, more RCTs are needed, with more patients and
longer follow-up.
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